-+ 0.00%
-+ 0.00%
-+ 0.00%

Curative Biotechnology, Inc. Issues Letter to Shareholders

Barchart·09/11/2026 06:00:00
Listen to the news

Company Reviews Significant Ophthalmology, Intellectual Property and Translational Development Milestones Achieved Over the Past Year

Palm Beach Gardens, FL, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) ("Curative" or the "Company"), a development-stage biomedical company advancing topical metformin-based ophthalmic therapies for degenerative eye diseases, today issued the following letter to shareholders and interested investors reviewing the Company's progress over the past year and outlining its priorities as it advances its ophthalmology platform.

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.